Susan E Carroll

US Patent:

20060003392, Jan 5, 2006

Filed:

May 11, 2005

Appl. No.:

11/128011

Inventors:

Esther Oh - San Diego CA, US
John Marcelletti - San Diego CA, US
Susan Carroll - San Diego CA, US
Katie Smith - Carlsbad CA, US

Assignee:

Prometheus Laboratories, Inc. - San Diego CA

International Classification:

G01N 33/53
G01N 33/569

US Classification:

435007310

Abstract:

The present invention provides methods for diagnosing the presence or severity of inflammatory bowel disease (IBD) in an individual and methods for stratifying IBD by determining the level of one or more IBD markers in a sample from the individual and calculating an index value using an algorithm based upon the level of the IBD markers. Methods for monitoring the efficacy of IBD therapy, monitoring the progression or regression of IBD, and optimizing therapy in an individual having IBD are also provided.

US Patent:

20060154276, Jul 13, 2006

Filed:

Dec 1, 2005

Appl. No.:

11/293616

Inventors:

Augusto Lois - San Diego CA, US
Bruce Neri - Carlsbad CA, US
Esther Oh - San Diego CA, US
John Marcelletti - San Diego CA, US
Susan Carroll - San Diego CA, US
Katie Smith - Carlsbad CA, US

Assignee:

Prometheus Laboratories Inc. - San Diego CA

International Classification:

C12Q 1/68
G01N 33/569
G01N 33/53

US Classification:

435006000, 435007310

Abstract:

The present invention provides methods for diagnosing inflammatory bowel disease (IBD) or for differentiating between Crohn's disease (CD), ulcerative colitis (UC), and indeterminate colitis (IC) in an individual by using a combination of learning statistical classifiers based upon the presence or level of one or more IBD markers in a sample from the individual. The present invention also provides methods for diagnosing the presence or severity of IBD and for stratifying IBD in an individual by determining the level of one or more IBD markers in a sample from the individual and calculating an index value using an algorithm based upon the level of the IBD markers. Methods for monitoring the efficacy of IBD therapy, monitoring the progression or regression of IBD, and optimizing therapy in an individual having IBD are also provided.